Valuation: Biocorrx Inc

Market Cap 11.62M 10.19M 9.41M 8.7M 16.48M 1.11B 16.81M 113M 43.96M 545M 43.64M 42.69M 1.89B P/E 2024
-0.78x
P/E 2025 -1.56x
Enterprise Value 13.62M 11.95M 11.03M 10.19M 19.32M 1.3B 19.71M 133M 51.53M 638M 51.16M 50.04M 2.22B EV / Sales 2024
1,004x
EV / Sales 2025 11.4x
Free-Float
38.64%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 58 2020-11-08
President 77 2024-01-04
Director TitleAgeSince
Director/Board Member 77 2019-02-28
Director/Board Member 66 2021-02-15
Director/Board Member 58 2018-03-31
Change 5-day change 1-year change 3-year change Capi.($)
-15.84%+6.09% - - 11.62M
+0.13%-0.32%+56.07%+51.03% 133B
-2.95%+4.42%+8.74%+40.87% 91.09B
-0.04%+0.74%+0.35%+72.62% 27.23B
-1.96%-3.62%+20.70%+49.79% 23.05B
-1.43%0.00%-19.81%-26.17% 20.25B
-1.23%+7.88%+19.65%+157.63% 17.77B
-1.53%+1.18%+60.45%+122.08% 14.81B
-2.15%-2.68%-1.96%+7.71% 14.51B
-0.51%+1.60%-10.76%-3.20% 12.86B
Average -2.74%+1.73%+14.83%+52.49% 39.43B
Weighted average by Cap. -1.15%+1.58%+26.58%+50.16%

Financials

2024 2025
Net sales 7.66K 6.72K 6.21K 5.74K 10.87K 734K 11.09K 74.62K 28.99K 359K 28.78K 28.15K 1.25M 797K 699K 646K 597K 1.13M 76.34M 1.15M 7.76M 3.02M 37.36M 2.99M 2.93M 130M
Net income -5.11M -4.48M -4.13M -3.82M -7.24M -489M -7.39M -49.71M -19.31M -239M -19.18M -18.75M -831M -3.44M -3.02M -2.79M -2.57M -4.88M -329M -4.98M -33.49M -13.01M -161M -12.92M -12.64M -560M
Net Debt 2.72M 2.38M 2.2M 2.03M 3.86M 260M 3.93M 26.46M 10.28M 127M 10.21M 9.98M 442M 2M 1.76M 1.62M 1.5M 2.84M 192M 2.9M 19.48M 7.57M 93.78M 7.52M 7.35M 326M
Logo Biocorrx Inc
BioCorRx Inc. is an addiction treatment solutions company. The Company is engaged in offering treatment for substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app, along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight-loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. It also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary, which is seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.
Employees
-